Pediatrix Medical Group Earnings Call Transcripts
Fiscal Year 2026
-
Strong Q1 results featured robust pricing and adjusted EBITDA of $58M, with revenue growth from acquisitions and favorable payer mix. Full-year adjusted EBITDA guidance of $280M–$300M is reaffirmed, and pricing is expected to moderate as the year progresses.
Fiscal Year 2025
-
Q4 2025 capped a strong year with adjusted EBITDA of $66M and full-year $276M, driven by favorable payer mix, acuity, and disciplined cost control. 2026 guidance projects flat revenue at $1.9B and 5% EBITDA growth, with steady operational metrics and no M&A included.
-
Adjusted EBITDA for Q3 2025 exceeded expectations at $87 million, driven by strong pricing, collections, and expense controls. Portfolio restructuring and acquisitions enhanced focus and performance, while full-year adjusted EBITDA guidance is set at $270–$290 million.
-
Q2 2025 adjusted EBITDA exceeded expectations, driven by strong same-unit revenue and NICU growth, while portfolio restructuring reduced total revenue. Full-year EBITDA guidance was raised, cash flow and balance sheet remain strong, and management is confident navigating regulatory and market headwinds.
-
First quarter results exceeded expectations with strong same-unit revenue and NICU volume growth, leading to a raised 2025 adjusted EBITDA outlook. Portfolio restructuring improved cost structure, and management remains cautious due to ongoing economic and healthcare uncertainty.
Fiscal Year 2024
-
Strong Q4 and year-end results were driven by favorable payer mix, volume growth, and portfolio restructuring, with Adjusted EBITDA exceeding guidance. 2025 outlook is cautious due to industry headwinds, with a focus on operational efficiency and maintaining a strong balance sheet.
-
Third-quarter results modestly exceeded expectations, with stable to positive patient volumes and strong same-unit revenue growth. Portfolio restructuring and RCM transition are on track, supporting improved cash flow and a narrowed full-year Adjusted EBITDA outlook of $205–$215 million.
-
Second quarter results exceeded expectations, driven by strong payer mix and operating efficiencies, with a one-time settlement boosting Adjusted EBITDA. Portfolio restructuring is underway, focusing on core hospital-based services and expected to add $30 million in annualized EBITDA.
-
Management is refocusing on core hospital-based maternal and neonatal services, exiting underperforming ambulatory practices, and seeing stable demand with growth in maternal-fetal medicine. Revenue cycle improvements and strong hospital partnerships support future acquisition and expansion plans.